Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 24, 2025

Primary Completion Date

March 23, 2026

Study Completion Date

March 23, 2027

Conditions

Radioiodine Refractory Differentiated Thyroid Cancer

Interventions

DRUG

177Lu-LNC1004 Injection

Intravenous administration: a single dose of 80 mCi per Cycle

Trial Locations (1)

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER